Drug Profile
Secretin - Sanochemia
Alternative Names: SecreluxLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Sanochemia Pharmazeutika
- Class Antipsychotics; Behavioural disorder therapies; Gastrointestinal hormones; Neuropeptides; Peptide diagnostics; Peptide hormones
- Mechanism of Action Magnetic resonance imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Pancreatic disorders; Zollinger-Ellison syndrome
- No development reported Pancreatitis
Most Recent Events
- 28 Nov 2018 No recent reports of development identified for clinical-Phase-Unknown development in Pancreatitis in Europe (IV, Injection)
- 14 Oct 2015 Clinical trials in Pancreatitis in Europe (IV) (Sanochemia pipeline, October 2015)
- 14 May 2013 Sanochemia's porcine synthetic secretin licensed to LINK Healthcare in Australia, New Zealand, Japan, South Africa and Asia (excluding Philippines and South Korea)